See more : World Houseware (Holdings) Limited (0713.HK) Income Statement Analysis – Financial Results
Complete financial analysis of IO Biotech, Inc. (IOBT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of IO Biotech, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Vertex Energy, Inc. (VTNR) Income Statement Analysis – Financial Results
- C WorldWide Globale Aktier – AK (CWIGAAKKKLA.CO) Income Statement Analysis – Financial Results
- Ulferts International Limited (1711.HK) Income Statement Analysis – Financial Results
- Venlon Enterprises Limited (VENLONENT.BO) Income Statement Analysis – Financial Results
- PolarX Limited (PXXXF) Income Statement Analysis – Financial Results
IO Biotech, Inc. (IOBT)
About IO Biotech, Inc.
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 756.00K | 540.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -756.00K | -540.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 67.83M | 46.99M | 30.15M | 8.46M | 7.94M |
| General & Administrative | 23.61M | 24.44M | 11.08M | 1.68M | 1.98M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 23.61M | 24.44M | 11.08M | 1.68M | 1.98M |
| Other Expenses | 0.00 | 0.00 | -26.54M | -1.99M | -781.00K |
| Operating Expenses | 91.44M | 71.42M | 41.23M | 10.15M | 9.91M |
| Cost & Expenses | 91.44M | 71.42M | 41.23M | 10.15M | 9.91M |
| Interest Income | 5.88M | 1.41M | 361.00 | 26.00 | 6.00 |
| Interest Expense | 0.00 | 302.00K | 361.00K | 26.00K | 6.00K |
| Depreciation & Amortization | 215.00K | 540.00K | 2.00K | 10.15M | 9.91M |
| EBITDA | -91.44M | -69.34M | -67.45M | 0.00 | -824.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -91.44M | -71.42M | -41.23M | -10.15M | -9.91M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 6.21M | 1.24M | -26.58M | -1.90M | -830.00K |
| Income Before Tax | -85.23M | -70.19M | -67.81M | -12.04M | -10.74M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 852.00K | 1.27M | 68.00K | 26.00K | 6.00K |
| Net Income | -86.08M | -71.46M | -67.88M | -12.07M | -10.75M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.98 | -2.48 | -2.36 | -0.42 | -0.37 |
| EPS Diluted | -1.98 | -2.48 | -2.36 | -0.42 | -0.37 |
| Weighted Avg Shares Out | 43.54M | 28.82M | 28.82M | 28.82M | 28.82M |
| Weighted Avg Shares Out (Dil) | 43.54M | 28.82M | 28.82M | 28.82M | 28.82M |
IO Biotech Announces New Data Related to its IO102-IO103 Therapeutic Cancer Vaccine Presented Today at the IASLC 2023 World Conference on Lung Cancer
NEW YORK, Sept. 12, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, announced that data from a pre-defined interim analysis related to the lung cohort...
IO Biotech Announces Participation in Upcoming Investor Conferences
NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, today announced its participation in the upcoming investor conferences:
IO Biotech Announces 2023 Second Quarter Results
NEW YORK, Aug. 11, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, today announced financial results for the second quarter ended June 30, 2023.
IO Biotech Appoints Heidi Hunter to its Board of Directors
NEW YORK, Aug. 11, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, announced the appointment of Heidi Hunter to its board of directors. Ms. Hunter,...
IO Biotech Announces Abstract Accepted for Poster Presentation at ESMO Congress 2023
NEW YORK, Aug. 08, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today an abstract related to the company's Phase 2 basket trial of...
IO Biotech, Inc. Announces $75 Million Private Placement Financing
NEW YORK, Aug. 07, 2023 (GLOBE NEWSWIRE) -- IO Biotech, Inc. (Nasdaq: IOBT), a clinical biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, today announced that it has entered into a definitive securities purchase agreement...
IO Biotech Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial at University of California Davis Comprehensive Cancer Center
NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, announced today that the University of California Davis Comprehensive Cancer Center has dosed...
IO Biotech Announces Abstract Accepted for Mini Oral Presentation at IASLC 2023 World Conference on Lung Cancer
NEW YORK, July 25, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today an abstract related to the company's Phase 2 basket trial (IOB-022/KN-D38)...
IO Biotech Strengthens Executive Management and US Presence with Appointment of Qasim Ahmad, MD, as Chief Medical Officer
NEW YORK, July 18, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, today announced the appointment of Qasim Ahmad, MD, as Chief Medical Officer. Dr....
IO Biotech (IOBT) Down Despite Positive Update on Melanoma Study
IO Biotech (IOBT) falls 25% despite achieving the clinical milestone of enrolling 225 patients in the advanced melanoma study evaluating the IO102-IO103/Keytruda combo.
Source: https://incomestatements.info
Category: Stock Reports